Pioneering access to this complex ophthalmic biosimilar medicine in the MENA Region
Lupin has partnered with Amman Pharmaceuticals Industries (Amman Pharma), a leading pharmaceutical manufacturer with operations across the MENA region and other global markets, for exclusive marketing and commercialisation of Ranibizumab, a biosimilar of Lucentis, in the Middle East region, including select territories of Jordan, Saudi Arabia, the UAE, Iraq, Lebanon, and other GCC countries. Both Lupin and Amman Pharma are united in their mission to provide innovative, high-quality healthcare solutions to patients in the MENA region.
“We aim to be at the forefront of transforming patient’s lives and building a healthier, brighter future for all. We are excited about the partnership with Amman Pharma to bring Ranibizumab to the MENA region,” said Nilesh Gupta, MD, Lupin.
“We aim to empower patients by offering timely and widespread access to cutting-edge biologic medication at affordable costs. Our successful development of biosimilar Ranibizumab stands as a testament to this commitment,” said Dr Cyrus Karkaria, President Biotechnology, Lupin. “Our mission in collaborating with Amman Pharma is to provide patients with advanced biologics that hold the promise of reshaping their health journey.”
Dr Fadi Alatrash, GM, Amman Pharma said, “We are proud to partner with Lupin, a world-leading biopharmaceutical company, to market and commercialise Ranibizumab. This partnership is aligned with our mission to provide high-quality products and access to advanced biosimilars to patients in the region. It also expands our biosimilar portfolio and strengthens our position in the niche ophthalmology market.”
